Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow IMPORTANT FDA ADVISORY
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Conte, P.
Right arrow Articles by Guarneri, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Conte, P.
Right arrow Articles by Guarneri, V.
The Oncologist, Vol. 9, Suppl 4, 28–37, September 2004
© 2004 AlphaMed Press

Safety of Intravenous and Oral Bisphosphonates and Compliance With Dosing Regimens

PierFranco Conte, Valentina Guarneri

Department of Oncology and Hematology, University Hospital, Modena, Italy

Correspondence: PierFranco Conte, M.D., Department of Oncology and Hematology, University Hospital, via del Pozzo 71, 41100 Modena, Italy. Telephone: 39-059-4224538/4224019 (secretary); Fax: 39-059-4224429; e-mail: conte.pierfranco{at}unimore.it

Patients with advanced cancers—particularly breast and prostate cancers—are at high risk for bone metastasis, leading to accelerated bone resorption and clinically significant skeletal morbidity. Bisphosphonates are effective inhibitors of bone resorption and reduce the risk of skeletal complications in patients with bone metastases. The standard routes of administration for bisphosphonates used in clinical practice are either oral or i.v. infusion. Oral administration of bisphosphonates is complicated by poor bioavailability (generally <5%) and poor gastrointestinal tolerability. First-generation bisphosphonates, such as clodronate (Bonefos®; Anthra Pharmaceuticals; Princeton, NJ), must be administered at high oral doses (1,600–3,200 mg/day) to achieve therapeutic effects, which leads to poor tolerability and compliance with oral dosing regimens. Infusion of bisphosphonates is associated with dose- and infusion-rate-dependent effects on renal function. In particular, high bisphosphonate doses (e.g., 1,500 mg clodronate) can cause severe renal toxicity unless infused slowly over many hours. In contrast, the newer, more potent bisphosphonates effectively inhibit bone resorption at micromolar concentrations, and the small doses required can be administered via relatively short i.v. infusions without adversely affecting renal function. Zoledronic acid (Zometa®; Novartis Pharmaceuticals Corp.; East Hanover, NJ) is a new generation bisphosphonate, and the recommended dose of 4 mg can be safely infused over 15 minutes. The 90-mg dose of pamidronate (Aredia®; Novartis Pharmaceuticals Corp.) and the 6-mg dose of ibandronate (Bondronat®; Hoffmann-La Roche Inc.; Nutley, NJ) require 1- to 4-hour infusions. Intravenous bisphosphonates require less frequent dosing (once a month) and are generally well tolerated with long-term use in patients with bone metastases. Zoledronic acid has demonstrated the broadest clinical activity in patients with bone metastases.

Key Words. Advanced cancer • Bone metastases • Bisphosphonates • Zoledronic acid




This article has been cited by other articles:


Home page
 The Journal of RheumatologyHome page
G. FAVIA, G. P. PILOLLI, and E. MAIORANO
Osteonecrosis of the Jaw Correlated to Bisphosphonate Therapy in Non-oncologic Patients: Clinicopathological Features of 24 Patients
J Rheumatol, December 1, 2009; 36(12): 2780 - 2787.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Beslija, J. Bonneterre, H. J. Burstein, V. Cocquyt, M. Gnant, V. Heinemann, J. Jassem, W. J. Kostler, M. Krainer, S. Menard, et al.
Third consensus on medical treatment of metastatic breast cancer
Ann. Onc., November 1, 2009; 20(11): 1771 - 1785.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
T. Van den Wyngaert, T. Claeys, M. T. Huizing, J. B. Vermorken, and E. Fossion
Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome
Ann. Onc., February 1, 2009; 20(2): 331 - 336.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. Van den Wyngaert, M. T. Huizing, E. Fossion, and J. B. Vermorken
Bisphosphonates in Oncology: Rising Stars or Fallen Heroes
Oncologist, February 1, 2009; 14(2): 181 - 191.
[Abstract] [Full Text] [PDF]

Home page
 Cleveland Clinic Journal of MedicineHome page
J. J. CAREY and L. PALOMO
Bisphosphonates and osteonecrosis of the jaw: Innocent association or significant risk?
Cleveland Clinic Journal of Medicine, December 1, 2008; 75(12): 871 - 879.
[Abstract] [Full Text] [PDF]

Home page
 J Dent EducHome page
A. Mariotti
Bisphosphonates and Osteonecrosis of the Jaws
J Dent Educ., August 1, 2008; 72(8): 919 - 929.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
M. Simonen, Y. Ibig-Rehm, G. Hofmann, J. Zimmermann, G. Albrecht, M. Magnier, V. Heidinger, and D. Gabriel
High-Content Assay to Study Protein Prenylation
J Biomol Screen, July 1, 2008; 13(6): 456 - 467.
[Abstract] [PDF]

Home page
 The OncologistHome page
A. M. Brufsky
Cancer Treatment-Induced Bone Loss: Pathophysiology and Clinical Perspectives
Oncologist, February 1, 2008; 13(2): 187 - 195.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
K. Olson and C. Van Poznak
Significance and impact of bisphosphonate-induced acute phase responses
Journal of Oncology Pharmacy Practice, December 1, 2007; 13(4): 223 - 229.
[Abstract] [PDF]

Home page
 Mayo Clin Proc.Home page
P. Kothawala, E. Badamgarav, S. Ryu, R. M. Miller, and R. J. Halbert
Systematic Review and Meta-analysis of Real-World Adherence to Drug Therapy for Osteoporosis
Mayo Clin. Proc., December 1, 2007; 82(12): 1493 - 1501.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D Aguiar Bujanda, U Bohn Sarmiento, M. Cabrera Suarez, and J Aguiar Morales
Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis
Ann. Onc., March 1, 2007; 18(3): 556 - 560.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. A. Guise
Bone Loss and Fracture Risk Associated with Cancer Therapy
Oncologist, November 1, 2006; 11(10): 1121 - 1131.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
T. Van den Wyngaert, M. T. Huizing, and J. B. Vermorken
Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?
Ann. Onc., August 1, 2006; 17(8): 1197 - 1204.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
M. Q. Lacy, A. Dispenzieri, M. A. Gertz, P. R. Greipp, K. L. Gollbach, S. R. Hayman, S. Kumar, J. A. Lust, S. V. Rajkumar, S. J. Russell, et al.
Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma
Mayo Clin. Proc., August 1, 2006; 81(8): 1047 - 1053.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Botteman, V. Barghout, J. Stephens, J. Hay, J. Brandman, and M. Aapro
Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases
Ann. Onc., July 1, 2006; 17(7): 1072 - 1082.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
G. Carteni, R. Bordonaro, F. Giotta, V. Lorusso, S. Scalone, V. Vinaccia, R. Rondena, and D. Amadori
Efficacy and Safety of Zoledronic Acid in Patients with Breast Cancer Metastatic to Bone: A Multicenter Clinical Trial
Oncologist, July 1, 2006; 11(7): 841 - 848.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
T. Tanvetyanon and P. J. Stiff
Management of the adverse effects associated with intravenous bisphosphonates
Ann. Onc., June 1, 2006; 17(6): 897 - 907.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
L. B. Michaud and S. Goodin
Cancer-treatment-induced bone loss, part 2
Am. J. Health Syst. Pharm., March 15, 2006; 63(6): 534 - 546.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Bell
Efficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data
Oncologist, October 1, 2005; 10(suppl_1): 8 - 13.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. A. Chabner
Late Toxicities of Drugs: Bisphosphonates
Oncologist, May 1, 2005; 10(5): 301 - 303.
[Full Text] [PDF]

Home page
 The OncologistHome page
G. Jackson
Safety and Compliance of Intravenous and Oral Dosing Regimens
Oncologist, May 1, 2005; 10(5): 313 - 314.
[Full Text] [PDF]

Home page
 The OncologistHome page
J.-J. Body
Bisphosphonate Safety and Tolerability
Oncologist, May 1, 2005; 10(5): 317 - 317.
[Full Text] [PDF]

Home page
 The OncologistHome page
P. Conte
Optimizing Bisphosphonate Therapy in Oncology
Oncologist, September 1, 2004; 9(suppl_4): 1 - 2.
[Full Text] [PDF]

Home page
 The OncologistHome page
R. E. Coleman
Bisphosphonates: Clinical Experience
Oncologist, September 1, 2004; 9(suppl_4): 14 - 27.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2004 by AlphaMed Press.
Advertisement